AI-generated analysis. Always verify with the original filing.
Caribou Biosciences, Inc. reported Q4 and full year 2025 financial results, including licensing and collaboration revenue of $3.9 million and $11.2 million, respectively, R&D expenses of $23.8 million and $109.4 million, and GAAP net loss of $26.5 million ($0.28 per share) and $148.1 million ($1.59 per share). The company provided clinical updates on vispa-cel and CB-011 programs and $142.8 million in cash as of December 31, 2025, sufficient into 2H 2027.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued by Caribou Biosciences, Inc. on March 5, 2026 104 Cover Page I
| Metric | Value | Basis |
|---|---|---|
| Licensing and collaboration revenue | $3.90 | |
| Licensing and collaboration revenue | $11.20 | |
| R&D expenses | $23.80 | |
| R&D expenses | $109.40 | |
| G&A expenses | $8.60 | |
| G&A expenses | $37.90 | |
| GAAP net loss | $26.50 | GAAP |
| GAAP net loss | $148.10 | GAAP |
| GAAP net loss per share | $0.28 | GAAP |
| GAAP net loss per share | $1.59 | GAAP |
| Non-GAAP net loss | $126.80 | Non-GAAP |
| Non-GAAP net loss per share | $1.36 | Non-GAAP |